Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in ...
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
When you give to Light Up A Lawn, Light Up A Life, you are supporting programs like Nationwide Children's cutting-edge gene ...
Editas Medicine (EDIT) will present updated safety and efficacy data in 28 patients living with severe sickle cell disease treated with ...
The latest announcement is out from Beam Therapeutics ( (BEAM) ).
Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, ...
BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19. Shares rise on this leadership transition.
Only one quarter of patients living with sickle cell disease are prescribed disease modifying therapies, particularly newer ...